File Download
  Links for fulltext
     (May Require Subscription)
  • Find via Find It@HKUL
Supplementary

Conference Paper: Prospective randomized trial of effect of direct renin inhibition in non-diabetic chronic kidney disease (DRINK): an interim analysis

TitleProspective randomized trial of effect of direct renin inhibition in non-diabetic chronic kidney disease (DRINK): an interim analysis
Authors
KeywordsMedical sciences
Urology and nephrology
Issue Date2012
PublisherAmerican Society of Nephrology. The Journal's web site is located at http://www.jasn.org
Citation
The 45th Annual Meeting of the American Society of Nephrology (Kidney Week 2012), San Diego, CA., 30 October-4 November 4 2012. In Journal of the American Society of Nephrology, 2012, v. 23 abstract suppl., p. 56A, abstract FR-OR115 How to Cite?
AbstractBACKGROUND: Aliskiren reduces proteinuria among type 2 diabetics in the AVOID study. However, the ALTITUDE trial has been prematurely terminated on account of increased adverse events at 18-24 months in the aliskiren arm. We report the interim results of the DRINK study initiated in 2009 to investigate the renoprotective potential and safety of aliskiren added to maximum-dose angiotensin receptor blocker (ARB) in non-diabetic CKD stage 3-4 (eGFR 15-59ml/min/1.73 m2) patients, with a planned follow-up time of 3 years. METHODS: Eligible patients receiving an ARB were randomly assigned aliskiren (150 mg titrated up to 300 mg daily) or conventional antihypertensive treatment to achieve blood pressure under 130/80 mmHg. The primary outcome was the composite of a doubling of baseline serum creatinine (sCr), ESRD or death. Analysis was by intention to treat. RESULTS: Seventy-six patients were randomized: 37 to aliskiren (27 male, mean age 55.0±11.1 y), and 39 to control (27 male, mean age 55.1±9.4 y). There was no difference in baseline demographics, sCr (194±61 vs. 214±65 mmol/l, P=0.15), eGFR (31.9±9.0 vs. 28.0±9.0 ml/min/1.73m2, P=0.06), serum K+ (4.3±0.5 vs. 4.4±0.6 mmol/l, P=0.23) and urine protein-to-creatinine ratio (98.8±19.0 vs. 74.4±10.9 mg/mmol, P=0.26) between the treatment vs. control group. After a median follow-up of 96 weeks (IQR: 64-112), two patients in each group reached the composite endpoint of doubling of sCr or ESRD (5.4% vs. 5.1%, P=0.769). The number of cardiovascular events was 4 (10.8%) vs. 1 (2.5%), P=0.217. Hyperkalemia (serum K+ >5.5 mmol/l) was encountered in 7 (18.9%) vs. 2 (5.1%) patients (P=0.045), which was controlled with resin therapy without withdrawing the study medications. There was no difference in the change in proteinuria between the 2 groups. CONCLUSIONS: Our interim results demonstrated no significant increase in adverse events except for more hyperkalemia in aliskiren-treated non-diabetic CKD stage 3-4 patients. The DRINK study will continue as planned. Funding: partially from the Yu Professorship in Nephrology Endowment Fund.
DescriptionFriday Oral Abstract - Potential Therapeutic Targets and Complications in CKD: abstract FR-OR115
Persistent Identifierhttp://hdl.handle.net/10722/185009
ISSN
2015 Impact Factor: 8.491
2015 SCImago Journal Rankings: 4.699

 

DC FieldValueLanguage
dc.contributor.authorTang, SCWen_US
dc.contributor.authorYap, DYHen_US
dc.contributor.authorMa, MKMen_US
dc.contributor.authorMok, MMY-
dc.contributor.authorLai, KN-
dc.date.accessioned2013-07-15T10:23:48Z-
dc.date.available2013-07-15T10:23:48Z-
dc.date.issued2012en_US
dc.identifier.citationThe 45th Annual Meeting of the American Society of Nephrology (Kidney Week 2012), San Diego, CA., 30 October-4 November 4 2012. In Journal of the American Society of Nephrology, 2012, v. 23 abstract suppl., p. 56A, abstract FR-OR115en_US
dc.identifier.issn1046-6673-
dc.identifier.urihttp://hdl.handle.net/10722/185009-
dc.descriptionFriday Oral Abstract - Potential Therapeutic Targets and Complications in CKD: abstract FR-OR115-
dc.description.abstractBACKGROUND: Aliskiren reduces proteinuria among type 2 diabetics in the AVOID study. However, the ALTITUDE trial has been prematurely terminated on account of increased adverse events at 18-24 months in the aliskiren arm. We report the interim results of the DRINK study initiated in 2009 to investigate the renoprotective potential and safety of aliskiren added to maximum-dose angiotensin receptor blocker (ARB) in non-diabetic CKD stage 3-4 (eGFR 15-59ml/min/1.73 m2) patients, with a planned follow-up time of 3 years. METHODS: Eligible patients receiving an ARB were randomly assigned aliskiren (150 mg titrated up to 300 mg daily) or conventional antihypertensive treatment to achieve blood pressure under 130/80 mmHg. The primary outcome was the composite of a doubling of baseline serum creatinine (sCr), ESRD or death. Analysis was by intention to treat. RESULTS: Seventy-six patients were randomized: 37 to aliskiren (27 male, mean age 55.0±11.1 y), and 39 to control (27 male, mean age 55.1±9.4 y). There was no difference in baseline demographics, sCr (194±61 vs. 214±65 mmol/l, P=0.15), eGFR (31.9±9.0 vs. 28.0±9.0 ml/min/1.73m2, P=0.06), serum K+ (4.3±0.5 vs. 4.4±0.6 mmol/l, P=0.23) and urine protein-to-creatinine ratio (98.8±19.0 vs. 74.4±10.9 mg/mmol, P=0.26) between the treatment vs. control group. After a median follow-up of 96 weeks (IQR: 64-112), two patients in each group reached the composite endpoint of doubling of sCr or ESRD (5.4% vs. 5.1%, P=0.769). The number of cardiovascular events was 4 (10.8%) vs. 1 (2.5%), P=0.217. Hyperkalemia (serum K+ >5.5 mmol/l) was encountered in 7 (18.9%) vs. 2 (5.1%) patients (P=0.045), which was controlled with resin therapy without withdrawing the study medications. There was no difference in the change in proteinuria between the 2 groups. CONCLUSIONS: Our interim results demonstrated no significant increase in adverse events except for more hyperkalemia in aliskiren-treated non-diabetic CKD stage 3-4 patients. The DRINK study will continue as planned. Funding: partially from the Yu Professorship in Nephrology Endowment Fund.-
dc.languageengen_US
dc.publisherAmerican Society of Nephrology. The Journal's web site is located at http://www.jasn.org-
dc.relation.ispartofJournal of the American Society of Nephrologyen_US
dc.relation.ispartofKidney Week 2012-
dc.subjectMedical sciences-
dc.subjectUrology and nephrology-
dc.titleProspective randomized trial of effect of direct renin inhibition in non-diabetic chronic kidney disease (DRINK): an interim analysisen_US
dc.typeConference_Paperen_US
dc.identifier.emailTang, SCW: scwtang@hku.hken_US
dc.identifier.emailYap, DYH: desmondy@hku.hken_US
dc.identifier.emailLai, KN: knlai@hku.hk-
dc.identifier.authorityTang, SCW=rp00480en_US
dc.identifier.authorityYap, DYH=rp01607en_US
dc.description.naturelink_to_OA_fulltext-
dc.identifier.hkuros215596en_US
dc.identifier.volume23-
dc.identifier.issueabstract suppl.-
dc.identifier.spage56A, abstract FR-OR115-
dc.identifier.epage56A, abstract FR-OR115-
dc.publisher.placeUnited States-

Export via OAI-PMH Interface in XML Formats


OR


Export to Other Non-XML Formats